Alector Inc (ALEC)

Feb 27, 2025, 1:09 AM EST - 9 days ago

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 10 days ago

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 8:00 AM EST - 11 days ago

Alector to Participate in Upcoming Healthcare Conferences

Feb 19, 2025, 4:05 PM EST - 17 days ago

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Jan 13, 2025, 8:00 AM EST - 7 weeks ago

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Dec 4, 2024, 2:20 PM EST - 3 months ago

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Nov 26, 2024, 10:29 AM EST - 3 months ago

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Nov 25, 2024, 4:05 PM EST - 3 months ago

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Nov 14, 2024, 4:05 PM EST - 4 months ago

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Nov 6, 2024, 4:05 PM EST - 4 months ago

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 11:53 PM EDT - 7 months ago

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 7 months ago

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 4:05 PM EDT - 7 months ago

Alector to Host Mid-Year Earnings Conference Call

Jul 28, 2024, 8:05 AM EDT - 7 months ago

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Jul 23, 2024, 7:00 AM EDT - 8 months ago

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Jun 10, 2024, 7:00 AM EDT - 9 months ago

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Feb 27, 2024, 11:23 PM EST - 1 year ago

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:05 PM EST - 1 year ago

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 20, 2024, 4:05 PM EST - 1 year ago

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Feb 8, 2024, 7:00 AM EST - 1 year ago

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

Feb 7, 2024, 7:00 AM EST - 1 year ago

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Jan 19, 2024, 9:20 AM EST - 1 year ago

Alector Announces Closing of Public Offering

Jan 17, 2024, 5:32 PM EST - 1 year ago

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Jan 17, 2024, 8:54 AM EST - 1 year ago

Alector Announces Pricing of Public Offering of Common Stock

Jan 16, 2024, 4:01 PM EST - 1 year ago

Alector Announces Proposed Public Offering of Common Stock

Jan 16, 2024, 11:12 AM EST - 1 year ago

Alector: Good Data, Huge Cash, No Near Term Catalyst

Nov 28, 2023, 7:00 AM EST - 1 year ago

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Nov 8, 2023, 7:00 AM EST - 1 year ago

Alector to Participate in the Stifel Healthcare Conference

Nov 7, 2023, 4:05 PM EST - 1 year ago

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 27, 2023, 7:00 AM EDT - 1 year ago

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Aug 4, 2023, 9:45 AM EDT - 1 year ago

Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript

Jun 6, 2023, 7:00 AM EDT - 1 year ago

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

May 4, 2023, 4:05 PM EDT - 2 years ago

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 7:00 AM EDT - 2 years ago

Alector to Participate in the BofA Securities 2023 Healthcare Conference

Feb 28, 2023, 4:05 PM EST - 2 years ago

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 3, 2023, 2:13 PM EST - 2 years ago

Alector: Trading At Cash Despite Late Stage CNS Pipeline

Dec 8, 2022, 4:30 PM EST - 2 years ago

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 29, 2022, 11:05 AM EST - 2 years ago

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

Oct 13, 2022, 8:00 AM EDT - 2 years ago

Alector Announces Promotion of Clare Hunt to Chief People Officer

Oct 4, 2022, 5:42 AM EDT - 2 years ago

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 3, 2022, 9:09 AM EDT - 2 years ago

MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An Edge

AAPL CAT CELH CLFD CVX DOW ENPH

Sep 12, 2022, 7:00 AM EDT - 2 years ago

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD)

Jun 14, 2022, 1:29 PM EDT - 2 years ago

Alector: Potential In Neurology And Cancer Treatments

Jun 8, 2022, 7:00 AM EDT - 2 years ago

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

May 27, 2022, 4:30 PM EDT - 3 years ago

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

May 4, 2022, 7:00 AM EDT - 3 years ago

Alector to Participate at the BofA Securities 2022 Healthcare Conference

Apr 16, 2022, 3:26 AM EDT - 3 years ago

Alector: Expect Phase 3 Data Next Year

Mar 29, 2022, 4:05 PM EDT - 3 years ago

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

Mar 24, 2022, 10:54 AM EDT - 3 years ago

Moore Kuehn, PLLC Encourages Investors of Alector, Inc. to Contact Law Firm

Mar 15, 2022, 8:00 AM EDT - 3 years ago

Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial